{Reference Type}: Journal Article
{Title}: Neoadjuvant chemotherapy followed by transoral robotic surgery versus upfront surgery for locoregionally advanced oropharyngeal carcinoma: A propensity score matched analysis.
{Author}: Sampieri C;Cioccoloni E;Costantino A;Kim D;Lee K;Meccariello G;Cammaroto G;Vicini C;Kim SH;
{Journal}: Head Neck
{Volume}: 0
{Issue}: 0
{Year}: 2024 Aug 1
{Factor}: 3.821
{DOI}: 10.1002/hed.27904
{Abstract}: <B>BACKGROUND: </B>Transoral robotic surgery (TORS) performed after neoadjuvant chemotherapy (NAC) is a promising treatment for advanced-stage oropharyngeal carcinoma (OPSCC) able to reduce the adjuvant therapy administration rate.<BR><B>METHODS: </B>A retrospective bi-centric study was conducted to analyze NAC + TORS versus upfront TORS patients. A 1:1 propensity score matching was used to compare the two groups.<BR><B>RESULTS: </B>Among the 300 patients with stage III-IV OPSCC, 204 patients were matched for comparing NAC + TORS versus upfront TORS. Between the two groups, no significant difference was observed in recurrences and in survival for RFS, OS, and DSS. In the NAC + TORS p16-positive population, adjuvant therapy could be spared in 51% versus 16% in the upfront surgery cohort (p < 0.001) due to the lower frequency of pathological risk factors after NAC.<BR><B>CONCLUSIONS: </B>NAC followed by TORS for locoregionally advanced OPSCC demonstrated to achieve non-inferior survival outcomes to upfront surgery, while in the p16-positive population allowed to significantly spare adjuvant therapy.